Bessemer Group Inc. Has $142.81 Million Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Bessemer Group Inc. increased its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 48.3% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 340,062 shares of the company's stock after purchasing an additional 110,816 shares during the period. Bessemer Group Inc. owned approximately 0.42% of IDEXX Laboratories worth $142,810,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. D.A. Davidson & CO. lifted its holdings in IDEXX Laboratories by 2.8% during the 4th quarter. D.A. Davidson & CO. now owns 1,674 shares of the company's stock valued at $692,000 after purchasing an additional 45 shares during the last quarter. Concurrent Investment Advisors LLC raised its position in IDEXX Laboratories by 36.7% in the 4th quarter. Concurrent Investment Advisors LLC now owns 861 shares of the company's stock valued at $356,000 after purchasing an additional 231 shares during the last quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund boosted its stake in IDEXX Laboratories by 13.5% in the fourth quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 20,992 shares of the company's stock worth $8,679,000 after purchasing an additional 2,500 shares in the last quarter. IFP Advisors Inc boosted its stake in IDEXX Laboratories by 3.6% in the fourth quarter. IFP Advisors Inc now owns 903 shares of the company's stock worth $373,000 after purchasing an additional 31 shares in the last quarter. Finally, BankPlus Trust Department bought a new stake in shares of IDEXX Laboratories during the fourth quarter worth $60,000. Institutional investors own 87.84% of the company's stock.

Insiders Place Their Bets

In other news, Director M Anne Szostak sold 1,260 shares of the business's stock in a transaction that occurred on Wednesday, May 21st. The stock was sold at an average price of $512.34, for a total transaction of $645,548.40. Following the completion of the sale, the director now owns 1,801 shares in the company, valued at $922,724.34. The trade was a 41.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 0.98% of the company's stock.

Wall Street Analyst Weigh In

IDXX has been the subject of a number of research analyst reports. Leerink Partners boosted their target price on shares of IDEXX Laboratories from $515.00 to $580.00 and gave the stock an "outperform" rating in a research note on Wednesday, June 11th. Morgan Stanley boosted their price objective on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a research report on Monday, May 5th. Stifel Nicolaus upped their price objective on IDEXX Laboratories from $460.00 to $510.00 and gave the stock a "hold" rating in a report on Monday, May 19th. Finally, Wall Street Zen lowered shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Friday, May 30th. Four research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $546.00.

IDEXX Laboratories Stock Down 0.5%

IDXX traded down $2.62 during trading hours on Thursday, hitting $527.78. 546,568 shares of the company's stock were exchanged, compared to its average volume of 645,538. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $538.01. The stock has a market cap of $42.44 billion, a price-to-earnings ratio of 48.78, a PEG ratio of 3.87 and a beta of 1.55. The company has a quick ratio of 0.81, a current ratio of 1.16 and a debt-to-equity ratio of 0.31. The stock's 50-day moving average is $494.30 and its two-hundred day moving average is $449.63.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The company reported $2.96 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.93 by $0.03. The company had revenue of $998.43 million during the quarter, compared to analysts' expectations of $998.25 million. IDEXX Laboratories had a return on equity of 57.35% and a net margin of 22.76%. The business's revenue was up 3.6% on a year-over-year basis. During the same period last year, the firm posted $2.71 earnings per share. Sell-side analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.